Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors
← catalyst calendarNCT05599984 · readout ≤ 467 d
Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
288actual
Sites
66
Countries
Australia, China, France +7
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-12-05 | actual | When the study began enrolling |
| Primary completion | Nov 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Nov 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2022-10-31 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-07 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Advanced Solid Tumors
Interventions
- Drug: ABBV-706
- Drug: Cisplatin
- Drug: Budigalimab — also filed as ABBV-181
- Drug: Carboplatin
Primary outcomes
what the primary-completion date above is the date OFPercentage of Participants With Adverse Events (AE)
measured Up to Approximately 2 Years
Maximum Observed Serum/Plasma Concentration (Cmax) of ABBV-706
measured Up to Approximately 2 Years
Time to Cmax (Tmax) of ABBV-706
measured Up to Approximately 2 Years
Terminal Phase Elimination Half-Life (t1/2) of ABBV-706
measured Up to Approximately 2 Years
Area Under the Serum/Plasma Concentration-Time Curve (AUC) of ABBV-706
measured Up to Approximately 2 Years
Antidrug Antibodies (ADAs)
measured Up to Approximately 2 Years
Neutralizing Antibodies (nAbs)
measured Up to Approximately 2 Years
Percentage of Participants with Objective Response, for Participants with Extracranial Solid Tumors
measured Up to Approximately 2 Years
Recommended Phase 2 Dose (RP2D) of ABBV-706
measured Up to Approximately 2 Years
Percentage of Participants with Objective Response for Participants with Central Nervous System (CNS) Tumors
measured Up to Approximately 2 Years
Duration of response (DOR) for Participants with Confirmed CR/PR
measured Up to Approximately 2 Years
Percentage of Participants with Clinical Benefit
measured Up to Approximately 2 Years
Progression-Free Survival (PFS)
measured Up to Approximately 2 Years
Overall survival (OS)
measured Up to Approximately 2 Years
Publications
- PMID 42225988 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed